





Heart Failure Performance Measures Update Writing Committee Chairs:
Michelle M. Kittleson, MD, PhD, FACC, FAHA, FHFSA, *Chair*





- In 2023, a 13-member writing committee was convened to update the measures from the 2020 heart failure measure set.
- The writing committee was charged with updating and developing new measures to evaluate the care of patients in accordance with the “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”.

Michelle M. Kittleson, MD, PhD, FACC, FAHA, FHFSA, Chair Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA, Vice Chair Boback Ziaeeian, MD, PhD, FACC, FAHA, JCPM Liaison	
David Aguilar, MD, MSc, FAHA	Paul A. Heidenreich, MD, MS, FACC, FAHA
Vanessa Blumer, MD	




1. This document describes performance measures for heart failure that are appropriate for public reporting or pay-for-performance programs (ie, a form of value-based purchasing).
2. The performance measures are taken from the “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines” and are selected from the strongest recommendations (Class 1 or 3).
3. Quality measures are also provided that are not yet ready for public reporting or pay-for-performance but might be useful for clinicians and healthcare organizations for quality improvement.
4. For all measures, if the clinician determines the care is not appropriate for the patient based on objective evidence to support decision-making, or if the patient declines treatment, that patient is excluded from the measure.








9. Highlighting the importance of multidisciplinary care, quality measures are added to emphasize targeting both known risks for




.....





- Developed from Class 1 class of recommendation (COR) and Level A and B level of evidence (LOE) (i.e., strong recommendations based on the highest quality of evidence).
- Designed to be considered for use in national quality payment and reporting programs by entities such as the Centers for Medicare & Medicaid Services (CMS) and the National Committee for Quality Assurance (NCQA).



- Based on lower ranges of CORs and LOEs.
- Designed to support quality improvement initiatives and activities at the national or microsystem levels.




Measure No.	Measure Title/Description	COR/LOE
Performance Measures		
PM-1	Start GDMT at Discharge From HF Hospitalization (Inpatient Setting)	COR: 1, LOE: B-NR
PM-2	BP Control in Patients With HFpEF BBf7 (r)evHaro Tc r7176 TmCle-3.a19 1.6nc (a)-3e.rG7	




Measure No.	Measure Title/Description	COR/LOE
Quality Measures		
QM-1	SGLT2 Inhibitor Therapy for Patients With HFmrEF or HFpEF (Inpatient and Outpatient Setting)	COR: 2a, LOE: B-R
QM-2	Screening and Documented Action for Social Determinants of Health for HF Patients (Inpatient and Outpatient Setting)	COR: 1, LOE: C-LD
QM-3	Counseling Regarding Contraception and the Risks of Cardiovascular Deterioration During Pregnancy in Individuals of Childbearing Potential With HF or Cardiomyopathy (Inpatient and Outpatient Setting)	COR: 1, LOE: C-LD; COR: 3, LOE: C-LD

COR indicates class of recommendation; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; LOE, level of evidence; QM, quality measure; and SGLT2, sodium-glucose cotransporter-2.



Measure No.	Measure Title/Description	COR/LOE
Quality Measures		
QM-4	Continuation of GDMT in Patients With HFimpEF to Prevent Relapse of Cardiomyopathy and Reduction in LVEF (Outpatient Setting)	COR: 1, LOE: B-R
QM-5	Optimizing GDMT in HFrEF Patients With Chronic Severe MR Secondary to LV Dysfunction Prior to TEER (Inpatient and Outpatient Setting)	COR: 1, LOE: B-R; COR: 1, LOE: C-LD
QM-6	Serum and Urine Monoclonal Protein Screen Performed in Patients Who Have Undergone Bone Scintigraphy for Suspected Cardiac Amyloidosis (Inpatient and Outpatient Setting)	COR: 1, LOE: B-R



Citations and Links to Heart Failure Performance Measures Update Publication